Non-small Cell Lung Cancer Clinical Trial
Official title:
Phase II Study of Imatinib Mesylate and Docetaxel in Pretreated Patients With Metastatic NSCLC
The goal of this clinical research study is to learn how effective the combination of the drugs imatinib mesylate (Gleevec®) and docetaxel (Taxotere®) is in treating non-small cell lung cancer (NSCLC). The safety and tolerability of this drug combination will also be studied.
Imatinib mesylate is a medication that blocks certain proteins important in the development
of cancer. Docetaxel is a drug that is designed to target and destroy cancer cells.
If you are found to be eligible to take part in this study, you will take 4 imatinib
mesylate tablets by mouth once a day. Docetaxel will be given through a vein in your arm on
the first day of each treatment cycle for a total of 6 cycles. The infusion will take 1
hour. A treatment cycle on this study is 21 days.
You will need to take steroids (dexamethasone) before receiving docetaxel to try to prevent
fluid accumulation and hypersensitivity reactions. The dexamethasone will come in a pill
form to be taken every 12 hours for 3 days starting the day before chemotherapy. You will
also receive additional dexamethasone by vein before the docetaxel is given.
After you complete 6 treatment cycles, you will continue to take 4 imatinib mesylate tablets
each day until your cancer gets worse, or you experience unacceptable side effects, or you
withdraw from the study.
While on this study, you will have a physical exam every 3 weeks. During the first 5 weeks
of the study, you will have blood tests each week. About 3 teaspoons of blood will be drawn
each time. After the first 5 weeks, you will have blood tests (3 teaspoons each) at the
beginning of each treatment cycle. In addition, your tumor will be measured by a CT or MRI
scan every 6 weeks.
You must agree not to use herbal remedies or other over-the-counter therapies (e.g., shark
cartilage) during treatment.
If you develop any unacceptable symptoms or changes in your laboratory tests, your treatment
may be delayed and/or the dose decreased until the symptoms are gone. It may even be
necessary to stop your treatment. Your doctor will inform you of any changes in your dosing
schedule or in the doses of your medication after he/she evaluates you in the clinic.
After treatment ends, you will have a follow-up visit at the clinic. At this visit, you will
have a complete physical exam, including blood (about 3 teaspoons) and urine tests. You will
also have a CT scan to measure the size of the tumor in your body.
This is an investigational study. Imatinib mesylate is FDA approved for the treatment of
leukemia. Docetaxel is FDA approved for the treatment of breast, prostate, and NSCLC. Up to
50 patients will take part in this study. All will be enrolled at UTMDACC.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |